Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ismail Khan

Showing results (131-140 of 139) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 139 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 StudyPatrick Neven, Nicole Stahl, Maria Vidal, et al.
Journal of the National Cancer Institute|November 12, 2020
Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging CouncilsLauren A Baldassarre, Eric H Yang, Richard K Cheng, et al.
Gene|November 13, 2023
Unveiling genetics of non-syndromic albinism using whole exome sequencing: A comprehensive study of TYR, TYRP1, OCA2 and MC1R genes in 17 familiesQaiser Zaman, Jamshid Khan, Mashal Ahmad, et al.
Gynecologic Oncology|October 23, 2024
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER studyKan Yonemori, Valentina Boni, Kim Gun Min, et al.
Journal of the American College of Cardiology|December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
Cardio-Oncology (London, England)|December 9, 2020
Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network surveyDiego Sadler, Jeanne M DeCara, Joerg Herrmann, et al.
Cancer Research|December 9, 2024
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast CancerShripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Translational Oncology|June 11, 2023
COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular diseaseMelissa Y Y Moey, Cassandra Hennessy, Benjamin French, et al.
Pageof 14

Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 StudyPatrick Neven, Nicole Stahl, Maria Vidal, et al.
Journal of the National Cancer Institute|November 12, 2020
Cardiovascular Care of the Oncology Patient During COVID-19: An Expert Consensus Document From the ACC Cardio-Oncology and Imaging CouncilsLauren A Baldassarre, Eric H Yang, Richard K Cheng, et al.
Gene|November 13, 2023
Unveiling genetics of non-syndromic albinism using whole exome sequencing: A comprehensive study of TYR, TYRP1, OCA2 and MC1R genes in 17 familiesQaiser Zaman, Jamshid Khan, Mashal Ahmad, et al.
Gynecologic Oncology|October 23, 2024
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER studyKan Yonemori, Valentina Boni, Kim Gun Min, et al.
Journal of the American College of Cardiology|December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
Cardio-Oncology (London, England)|December 9, 2020
Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network surveyDiego Sadler, Jeanne M DeCara, Joerg Herrmann, et al.
Cancer Research|December 9, 2024
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast CancerShripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER StudyKomal L Jhaveri, Elgene Lim, Rinath Jeselsohn, et al.
Translational Oncology|June 11, 2023
COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular diseaseMelissa Y Y Moey, Cassandra Hennessy, Benjamin French, et al.
Pageof 14